Isoquercitrin Solubility via L-Arginine and Ascorbate Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Isoquercitrin has low oral absorption due to its relatively low water solubility, requiring high doses for bioavailability, and existing modifications like enzymatically modified isoquercitrin are impractical for human use as they are mixtures of bioactive derivatives, violating FDA guidelines.
Innovation Solution
A water-soluble pharmaceutical composition containing isoquercitrin, L-arginine, and an alkali salt of ascorbic acid, with a specific molar ratio, enhancing bioavailability without the drawbacks of existing modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of isoquercitrin are administered to achieve sufficient bioavailability, then absorption is improved, but the dose becomes unusually high compared to typical pharmaceuticals
Solution Approach 1:
The patent introduces L-arginine and ascorbic acid alkali salt as intermediary substances that facilitate isoquercitrin absorption. These mediators form complexes with isoquercitrin, improving its water solubility and facilitating transport across the intestinal membrane, thereby achieving better bioavailability at lower doses.
Solution Approach 2:
The patent changes the chemical parameters of isoquercitrin by combining it with L-arginine and ascorbic acid alkali salt in specific molar ratios (1:1.6-2.6:0.16-1.95). This parameter modification alters the solubility and permeation characteristics of isoquercitrin, enabling improved absorption without requiring unusually high doses.
2Reliability
If enzymatically modified isoquercitrin is used to improve water solubility, then bioavailability is improved, but the composition becomes a mixture of multiple bioactive derivatives that is impractical for human use
Solution Approach 1:
The patent extracts and isolates specific functional components (L-arginine and ascorbic acid alkali salt) that are responsible for improving isoquercitrin solubility and absorption. Instead of using a complex mixture of enzymatically modified derivatives, the patent identifies and combines these key components in a simplified formulation that maintains bioavailability improvement while reducing compositional complexity.
Solution Approach 2:
The patent applies local quality modification by selectively modifying isoquercitrin through combination with L-arginine and ascorbic acid alkali salt, rather than performing broad enzymatic modification that produces multiple derivatives. This localized approach modifies only the necessary properties (solubility and permeation) while maintaining the integrity of the main isoquercitrin molecule.
3Ease of manufacture
If isoquercitrin is administered alone, then the formulation is simple, but water solubility is low resulting in poor oral absorption
Solution Approach 1:
The patent merges isoquercitrin with L-arginine and ascorbic acid alkali salt in a single pharmaceutical composition. This combination creates a synergistic effect where the merged formulation maintains relative simplicity while dramatically improving water solubility and oral absorption through the cooperative action of all three components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly improves isoquercitrin absorption, achieving higher plasma concentrations and bioavailability, as demonstrated by increased permeation rates and pharmacokinetic profiles compared to isoquercitrin alone, with improved stability and bioavailability metrics.
Implementation Method 1
Enzymatically modified isoquercitrin (EMIQ) with higher water solubility has been developed to improve the bioavailability of isoquercitrin
Implementation Method 2
The composition significantly improves isoquercitrin absorption, achieving higher plasma concentrations and bioavailability, as demonstrated by increased permeation rates and pharmacokinetic profiles
Data Source
Figure 1
AI summary
A water-soluble pharmaceutical composition containing isoquercitrin, L-arginine, and ascorbic acid or an alkali salt thereof, in which the molar ratio between the isoquercitrin, L-arginine, and the ascorbic acid or alkali salt is 1: 1.6-2.6: 0.16-1.95.